Full-Time

Responsable de l'Excellence Opérationnelle Groupe

Posted on 10/7/2025

LFB

LFB

1,001-5,000 employees

Public health biopharmaceuticals via plasma-derived products

No salary listed

Paris, France

Hybrid

Up to 2 days of telecommuting per week after 4 months of employment.

Category
Operations & Logistics (2)
,
Required Skills
Minitab
Data Analysis
Excel/Numbers/Sheets
Requirements
  • Master 2 or Engineering degree
  • Ideally certified Green Belt or Black Belt in Six Sigma and Lean Manufacturing
  • Confirmed experience in Production, Supply Chain, or Quality
  • Ability to analyze data
  • Confirmed skills in performance and cost management
  • Expertise in Lean 6 sigma tools
  • Advanced mastery of Office Pack (Excel) and database tools, Minitab would be a plus
  • Positive leadership, coaching
  • Interpersonal and cooperation skills
  • Execution discipline, results orientation in the company's values
Responsibilities
  • Launch, pilot and/or participate in operational excellence projects linked to site-defined objectives to improve quality, performance, efficiency, and costs
  • Train and coach teams on Lean Manufacturing tools
  • Provide necessary support to the Management Committee to identify strategic and performance improvements
  • Conduct comparative analyses to help identify the best solutions
  • Promote and utilize tools and techniques necessary for continuous improvement and value creation
  • Encourage cultural change by sharing best practices and solutions, knowledge of tools and continuous improvement processes across LFB
Desired Qualifications
  • Familiarity with Minitab would be a plus

LFB is a French biopharmaceutical company that develops and manufactures medicines from plasma and biotech products. It collects plasma, fractionates it into medicines, and also produces recombinant proteins for rare diseases in immunology and hemostasis, sold in many countries. It stands out because it started as a state-initiated public health mission and remains state-owned with the French State as sole shareholder, plus vertical integration through acquisitions of plasma collection firms. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharma player.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Courcebœufs, France

Founded

1994

Simplify Jobs

Simplify's Take

What believers are saying

  • ESCAPE strategy doubles bioproduction capacity by 2025.
  • Amber Plasma acquisition boosts Czech centers to 24.
  • Arras site triples medication production for patient demand.

What critics are saying

  • FDA bans cripple LFB USA rPRO™ proteins in 12-18 months.
  • CSL Behring squeezes Europlasma's 24 centers in 6-12 months.
  • Grifols captures 25% hemostasis share in 12-24 months.

What makes LFB unique

  • LFB specializes in plasma-derived medicines from 1994 French state initiative.
  • rPRO™ technology expresses recombinant proteins in transgenic animal milk.
  • Europlasma secures plasma via 24 Central European collection centers.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Paid Vacation

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Stock Options

Company Equity

Conference Attendance Budget

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Education allowance

Tuition Reimbursement

Company News

MyPharma Editions
May 30th, 2024
LFB Acquires Amber Plasma in Czech Republic

Title: "LFB Acquires Amber Plasma in the Czech Republic" LFB and its subsidiary Europlasma have acquired Amber Plasma, which operates 12 plasma collection centers in the Czech Republic. This acquisition increases Europlasma's total to 24 centers in Central Europe, enhancing LFB's plasma collection capacity. The move supports LFB's goal to meet growing patient demand and will aid in the launch of a new production site in Arras, France, tripling its medication production capacity.

INACTIVE